Abstract
Tamoxifen, a nonsteroidal antiestrogen, was first approved by the Food and Drug Administration in 1978 for the treatment of patients with breast cancer. Large clinical trials involving over 75,000 patients have demonstrated an improved recurrence-free and overall survival benefit in both premenopausal and postmenopausal women. Long-term adjuvant tamoxifen is the endocrine treatment of choice for selected patients with breast cancer, and there are currently large-scale trials to evaluate its role as a chemopreventative agent in healthy women at risk for breast cancer. Consequently, a large number of women, including healthy young patients with no history of cancer, will be subjected to the long-term effects of tamoxifen. One of the most significant complications of long-term tamoxifen use is the possible development of endometrial cancer. The purpose of this chapter is to review the current literature regarding tamoxifen use in breast cancer patients and associated benign and malignant uterine neoplasia. In addition, the role of screening for endometrial cancer in tamoxifen-treated breast cancer patients is explored.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Satyaswaroop PG, Zaino RJ, Mortel R. 1984. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 44:4006–4010.
Gottardis MM, Robinson SP, Satyaswaroop PG, et al. 1988. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48:812–815.
Wolf DM, Jordan VC. 1992. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol 45:118–128.
Tucker MJ, Adams HK, Patterson JS. 1984. In Laurence DR, Mclean AEM, Weatherall M, eds Safety Testing of New Drugs. New York: Academic Press, pp. 125–161.
Han XL, Liehr JG. 1992. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52:1360–1363.
White IN, De Matteis F, Davies A, et al. 1992. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13:2197–2203.
Martin EA, Rich KJ, White INH, et al. 1995. 32P-Postlabeled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 16:1651–1654.
Pongracz K, Pathak DN, Nakamura T, et al. 1995. Activation of the tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res 55:3012–3015.
Carmichael PL, Ugwumanda AHN, Neven P, et al. 1996. Lack of genotoxicity of tamoxifen in the human endometrium. Cancer Res 56:1475–1479.
Boccardo F, Bruzzi P, Rubagotti A, et al. 1981. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 38:281–285.
Lahti E, Blanco G, Kauppila A, et al. 1993. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81:660–664.
Corley D, Rowe J, Curtis MT, et al. 1992. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 79:111–116.
Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder Y. 1990. Hysteroscopic follow up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol 35:235–238.
Cohen I, Rosen DJD, Shapira J, et al. 1994. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and non-treated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 52:185–190.
Gal D, Kopel S, Bashevkin M, et al. 1991. Oncologic potential of tamoxifen on endometria of postmenopausal women with breast cancer: preliminary report. Gynecol Oncol 42:120–123.
Gibson LE, Barakat RR, Venkatraman ES, et al. 1995. Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and nonusers. Cancer J Sci Am 2:35–38.
Kedar RP, Bourne TH, Powles TJ, et al. 1994. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343:1318–1321.
Hacker NF, Moore JG, eds. 1992. Essentials of Obstetrics and Gynecology, 2nd ed. Philadelphia: WB Saunders, p. 577.
Killackey MA, Hakes TB, Pierce VK. 1985. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69:237–238.
Assikis VJ, Jordan VC. 1995. Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynecol Obstet 49:241–257.
Fornander T, Cedermark B, Mattsson A, et al. 1989. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1:117–120.
Fisher B, Costantino JP, Redmond CK, et al. 1994. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527–537.
National Cancer Institute. 1993. SEER Cancer Statistics Review 1973–1990. Document #93–2789. Bethesda, MD: NCI.
Rutqvist LE, Johansson H, Signomklao T, et al. 1995. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87:645–651.
Elwood JM, Boyes DA. 1980. Clinical and pathological features and survival of endometrial cancer patients in relation to prior use of estrogens. Gynecol Oncol 10:173–187.
Magriples U, Naftolin F, Schwartz PE, et al. 1993. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11:485–490.
Silva EG, Tornos CS, Follen-Mitchell M. 1994. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol 13:248–258.
Barakat RR, Wong G, Curtin JP, et al. 1994. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 55:164–168.
Fornander T, Hellstrom A-C, Moberger B. 1993. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 85:1850–1855.
Van Leeuwen FE, Benraadt J, Coebergh JWW, et al. 1994. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448–452.
Barakat RR, Gilewski TA, Saigo PE, et al. 1995. The effect of adjuvant tamoxifen on the endometrium in women with breast cancer: an interim analysis of a prospective study (abstract). Proc ASCO 779.
Cohen I, Rosen D, Tepper R, et al. 1993. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 5:275–280.
Goldstein SR. 1994. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 170:447–451.
Barakat RR, Adhikari D, Saigo PE, O’Connor B, Banerjee D, Bertino JR. In press. Mutation of c-Ki-ras in tamoxifen-associated endometrial carcinoma. Accepted for presentation, Society of Gynecologic Oncologists’ Annual Meeting, 1996.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Barakat, R.R. (1998). Tamoxifen and the endometrium. In: Foon, K.A., Muss, H.B. (eds) Biological and Hormonal Therapies of Cancer. Cancer Treatment and Research, vol 94. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-6189-7_11
Download citation
DOI: https://doi.org/10.1007/978-1-4615-6189-7_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7837-2
Online ISBN: 978-1-4615-6189-7
eBook Packages: Springer Book Archive